Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Total Debt (2016 - 2025)

Historic Total Debt for NovaBay Pharmaceuticals (NBY) over the last 10 years, with Q3 2025 value amounting to $149000.0.

  • NovaBay Pharmaceuticals' Total Debt rose 19215.69% to $149000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $149000.0, marking a year-over-year increase of 19215.69%. This contributed to the annual value of $65000.0 for FY2024, which is 9428.32% down from last year.
  • According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' Total Debt is $149000.0, which was up 19215.69% from $111000.0 recorded in Q2 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' Total Debt peaked at $1.3 million during Q3 2023, and registered a low of $51000.0 during Q3 2024.
  • Its 4-year average for Total Debt is $525909.1, with a median of $149000.0 in 2025.
  • Its Total Debt has fluctuated over the past 5 years, first plummeted by 9598.43% in 2024, then soared by 19215.69% in 2025.
  • Over the past 4 years, NovaBay Pharmaceuticals' Total Debt (Quarter) stood at $105000.0 in 2021, then skyrocketed by 982.86% to $1.1 million in 2023, then plummeted by 94.28% to $65000.0 in 2024, then skyrocketed by 129.23% to $149000.0 in 2025.
  • Its last three reported values are $149000.0 in Q3 2025, $111000.0 for Q2 2025, and $84000.0 during Q1 2025.